logo inserm ifrb fondateurCC logoUSPN

Publications du Li2P INSERM UMR 1125

Publications du Li2P INSERM UMR 1125

2018

  • Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. E. Peranzoni, J. Lemoine, L. Vimeux, V. Feuillet, S. Barrin, C. Kantari, N. Bercovici, M. Guerin, J. Biton, H. Ouakrim, F. Regnier, A. Lupo, M. Alifano, D. Damotte, E.Donnadieu. Proceedings of the National Academy of Sciences. 2018 Apr 24;115(17):E4041-E4050.
  • Impaired tumor-infiltrating T cells in patients with COPD impacts lung cancer response to PD-1. blockade.J. Biton, H. Ouakrim,A. Dechartres, M. Alifano, A. Mansuet-Lupo, H. Si, R. Halpin, T. Creasy, C. Bantsimba-Malanda, J. Arrondeau,F. Goldwasser, P. Boudou-Rouquette, L.Fournel, N. Roche, P-R. Burgel, J. Goc, P. Devi-Marulkar, C. Germain, M-C. Dieu-Nosjean, I. Cremer, R. Herbst, D. Damotte. American Journal of Respiratory and Critical Care Medicine.2018 Oct 1;198(7):928-940.
  • TP53, STK11 and EGFR Mutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma. J. Biton, A. Mansuet-Lupo, N. Pécuchet, M. Alifano, H. Ouakrim, J. Arrondeau, P. Boudou-Rouquette, F. Goldwasser, K. Leroy, J. Goc, C. Germain, P. Laurent-Puig, M-C. Dieu-Nosjean, I. Cremer, R. Herbst, H. Blons, D. Damotte.Clinical Cancer Research. 2018 Nov 15;24(22):5710-5723.
  • Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. V. M. Braud, J. Biton, E. Becht, S. Knockaert, A. Mansuet-Lupo, E. Cosson, D. Damotte, M. Alifano, P. Validire, F. Anjuère, I. Cremer, N. Girard, D.Gossot, A.Seguin-Givelet, M-CDieu-Nosjean & C. Germain. Oncoimmunology. 2018 Dec 8; 5 (12).
  • MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562.

2017

  • Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.Belmellat. N, Semerano L, Segueni N, Damotte D, Decker P, Ryffel B, Quesniaux V, Boissier MC, Assier E. Front Immunol. 2017 Nov 14;8:1533
  • Salt, inflammatory joint disease, and autoimmunity. Sigaux J, Semerano L, Favre G, Bessis N, Boissier MC. Joint Bone Spine. 2017 Jun 23. pii: S1297-319X(17)30129-X. doi: 10.1016/j.jbspin.2017.06.003.
  • Developments with experimental and investigational drugs for axial spondyloarthritis. Clavel G, Boissier MC, Sigaux J, Semerano L. Expert Opin Investig Drugs. 2017 Jul;26(7):833-842. doi: 10.1080/13543784.2017.1337744
  • Do we need animal models to advance research on inflammatory joint disease? Boissier MC, Bessis N. Joint Bone Spine. 2017 Jul;84(4):381-383
  • Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Clavel G, Moulignier A, Semerano L. Joint Bone Spine. 2017 Dec;84(6):671-675. Doi : 10.1016/j.jbspin.2017.03.002. 2017 Mar 18.
  • Arthritis models: usefulness and interpretation. Bessis N, Decker P, Assier E, Semerano L, Boissier MC. Semin Immunopathol. 2017 Jun;39(4):469-486. doi: 10.1007/s00281-017-0622-4.
  • Nutrition and chronic inflammatory rheumatic disease. Semerano L, Julia C, Aitisha O, Boissier MC. Joint Bone Spine. 2017 Oct;84(5):547-552. doi: 10.1016/j.jbspin.2016.10.003.
  • Developments with experimental and investigational drugs for axial spondyloarthritis. Clavel G, Boissier MC, Sigaux J, Semerano L. Expert Opin Investig Drugs. 2017 Jul;26(7):833-842. doi: 10.1080/13543784.2017.1337744.
  • Vaccination Is Suitable for Treating Inflammatory Diseases. Assier E, Bessis N, Zagury JF, Boissier MC. Front Pharmacol. 2017 Jan 31;8:6. doi: 10.3389/fphar.2017.00006.
  • Vitamin D supplementation in patients treated for sarcoidosis: Controversy or consensus? Saidenberg-Kermanac'h N, Valeyre D, Boissier MC. Joint Bone Spine. 2017 Oct;84(5):521-523

2016

  • In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, Delavallée L, Levescot A, Roga S, Decker P, Girard JP, Herbelin A, Boissier MC, Bessis N. J Immunol. 2016 Sep 1;197(5):1708-19. doi: 10.4049/jimmunol.1502124.
  • Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Semerano L, Decker P, Clavel G, Boissier MC. Expert Opin Investig Drugs. 2016 Dec;25(12):1355-1359.
  • Personality modulates proportions of CD4+ regulatory and effector T cells in response to socially induced stress in a rodent of wild origin. Rangassamy M, Khaleghparast Athari S, Monclús R, Boissier MC, Bessis N, Rödel HG. Physiol Behav. 2016 Dec 1;167:255-264. doi: 10.1016/j.physbeh.2016.09.016.
  • Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Minichiello E, Semerano L, Boissier MC. Joint Bone Spine. 2016 Dec;83(6):625-630. doi: 10.1016/j.jbspin.2016.07.007.
  • Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Athari SK, Poirier E, Biton J, Semerano L, Hervé R, Raffaillac A, Lemeiter D, Herbelin A, Girard JP, Caux F, Boissier MC, Bessis N. Arthritis Res Ther. 2016 Jun 18;18(1):143. doi: 10.1186/s13075-016-1042-x.
  • Novel Immunotherapeutic Avenues for Rheumatoid Arthritis. Semerano L, Minichiello E, Bessis N, Boissier MC. Trends Mol Med. 2016 Mar;22(3):214-29. doi: 10.1016/j.molmed. 2016.01.005. Review.
  • Aortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritis. Denys A, Clavel G, Lemeiter D, Schischmanoff O, Boissier MC, Semerano L. J Cell Mol Med. 2016 May;20(5):855-63. doi: 10.1111/jcmm.12790.
  • Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. Perez J, Dansou B, Hervé R, Levi C, Tamouza H, Vandermeersch S, Demey-Thomas E, Haymann JP, Zafrani L, Klatzmann D, Boissier MC, Letavernier E, Baud L. J Immunol. 2016 Jan 1;196(1):168-81. doi: 10.4049/jimmunol.1500749.
  • Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis. Semerano L, Duvallet E, Belmellat N, Marival N, Schall N, Monteil M, Grouard-Vogel G, Bernier E, Lecouvey M, Hlawaty H, Muller S, Boissier MC, Assier E. Angiogenesis. 2016 Jan;19(1):39-52. doi: 10.1007/s10456-015-9487-0.

2015

  • Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis. Semerano L, Duvallet E, Belmellat N, Marival N, Schall N, Monteil M, Grouard-Vogel G, Bernier E, Lecouvey M, Hlawaty H, Muller S, Boissier MC, Assier E. . Angiogenesis. 2015 Sep 29.
  • Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes. Challal S, Minichiello E, Boissier MC, Semerano L.   Joint Bone Spine. 2015 Jul 13.
  • Metabolomics for rheumatic diseases: has the time come? Semerano L, Roméo PH, Boissier MC.   Ann Rheum Dis. 2015 Jul;74(7):1325-6

Plus d'articles...

  1. 2014
  2. 2013
  3. 2012
  4. 2011
  5. 2010
  6. 2009
  7. 2008
  8. 2007
  9. 2006
  10. 2005
  11. 2004
  12. 2003
  13. 2002
  14. 2001
  15. 2000

USPN Campus de Bobigny

tour illustration bobigny

web li2p V3

-->